米利诺的使用与心脏手术后的术后心房动有关
Gregory A Fleming1, Katherine T Murray, Chang Yu
1Division of Pediatric Cardiology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Circulation
|October 1, 2008
概括
米利诺使用显著增加了心脏手术后术后心房动 (AF) 的风险. 这一发现突出了在管理接受这些手术的患者时需要考虑的关键因素.
科学领域:
- 心脏病学 心脏病学
- 心脏外科手术 心脏外科手术
- 药理学 药理学是指药理学的学科.
背景情况:
- 手术后心房动 (AF) 是心脏手术后的常见并发症,导致发病率增加和住院时间更长.
- 内类药物经常在外科手术期间使用,以支持心脏功能.
- 无otropic药物使用和术后AF的发展之间的联系需要进一步调查.
研究的目的:
- 调查一种假设,即内托普药物管理与术后心房动 (AF) 的发病率增加有关.
主要方法:
- 一组232名接受选择性心脏手术的患者被评估为外科手术期间的危险因素.
- 收集了患者人口统计数据,并发症,手术程序和术后药物的数据.
- 用多变量逻辑回归分析来确定术后AF的独立预测因子.
主要成果:
- 术后心房 (AF) 在28.9%的患者中发生,与更长的住院时间和增加的死亡率有关.
- 米利诺的使用与患上术后肌前膜炎的风险更高 (58.2%与26.1%) 有关.
- AF的独立预测因素包括年龄较大,较低的射出分数和米利诺尼使用 (OR 4.86).
结论:
- 密利诺因被确定为选择性心脏手术后发生术后心房动的独立风险因素.
- 这些发现表明,在术后期仔细考虑使用milrinone可能是有必要的,以减轻AF风险.
相关概念视频
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Mitral Regurgitation III: Medical Management
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...


